8642 Background: Osimertinib is broadly used for advanced EGFR-mutant NSCLC patients.
However, the activity of osimertinib is not fully characterized in tumors harboring uncommon …

Introduction EGFR mutations drive a subset of NSCLC. Patients harboring the common
EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third …

Importance Non–small cell lung cancer (NSCLC) with uncommonEGFRmutations is a rare
subgroup, composing 14% of allEGFRmutations. Objective To determine the usefulness of …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Background In 10-20% of patients (pts) with EGFR mutated NSCLC, an assorted group of
uncommon mutations can be detected. These mutations confer variable sensitivity to 1st and …

Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …

Introduction EGFR tyrosine kinase inhibitors (TKIs) are more effective than chemotherapy in
patients with EGFR-mutant NSCLC. Disease progression on EGFR TKI therapy occurs most …

Background The FLAURA study reported the efficacy of Os as first-line treatment for EGFR
mutation-positive NSCLC (EGFRmNSCLC), and upfront Os was introduced into clinical …

Epidermal growth factor receptor (EGFR)-mutated (exons 18–21) advanced non-small cell
lung cancers (NSCLCs) are generally characterized by exquisite sensitivity to treatment with …

Background Osimertinib is a recently approved third-generation epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …